Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | HPGD | P15428 | 3/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | SYK | P43405 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 5/20 | 0.31 |
| ▸ | CA1 | P00915 | 5/20 | 0.31 |
| ▸ | CA2 | P00918 | 5/20 | 0.31 |
| ▸ | CA9 | Q16790 | 5/20 | 0.31 |
| ▸ | RAB9A | P51151 | 3/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16971159 | 0.96 | ALDH1A1 (0.32) | MAPTALDH1A1HPGDTSHRLMNA | |
| SCHEMBL16971270 | 0.96 | SYK (0.32) | MAPTALDH1A1HPGDTSHRLMNA | |
| SCHEMBL16971156 | 0.93 | SYK (0.34) | MAPTSYKCA12CA1CA2 | |
| SCHEMBL16971210 | 0.89 | SYK (0.33) | SYK | |
| SCHEMBL16971178 | 0.89 | IDO1 (0.32) | SYKCA12CA1CA2CA9 | |
| SCHEMBL16979596 | 0.87 | — | — | |
| SCHEMBL16971230 | 0.86 | ALDH1A1 (0.35) | MAPTALDH1A1HPGDTSHRLMNA | |
| SCHEMBL16971236 | 0.85 | MAPT (0.34) | MAPTALDH1A1HPGDTSHRLMNA | |
| SCHEMBL16971220 | 0.85 | MAPT (0.34) | MAPTALDH1A1HPGDTSHRLMNA | |
| SCHEMBL16979599 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106132406-B | β -substituted gamma-amino acids and analogs as chemotherapeutic agents | 夸德里加生物科学公司 | 2020-03-27 | — | — | CN | disclosed |
| US-9937139-B2 | β-substituted γ-amino acids and analogs as chemotherapeutic agents | QUADRIGA BIOSCIENCES, INC. (US) | 2018-04-10 | — | — | US | disclosed |
| US-20170246135-A1 | BETA-SUBSTITUTED GAMMA-AMINO ACIDS AND ANALOGS AS CHEMOTHERAPEUTIC AGENTS | QUADRIGA BIOSCIENCES, INC. | 2017-08-31 | — | — | US | disclosed |
| US-9682921-B2 | β-substituted γ-amino acids and analogs as chemotherapeutic agents | QUADRIGA BIOSCIENCES, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| EP-3102194-A1 | BETA-SUBSTITUTED GAMMA-AMINO ACIDS AND ANALOGS AS CHEMOTHERAPEUTIC AGENTS | Quadriga Biosciences, Inc. (US) | 2016-12-14 | — | — | EP | disclosed |
| US-20160289168-A1 | BETA-SUBSTITUTED GAMMA-AMINO ACIDS AND ANALOGS AS CHEMOTHERAPEUTIC AGENTS | QUADRIGA BIOSCIENCES, INC. | 2016-10-06 | — | — | US | disclosed |
| US-9394236-B2 | β-substituted γ-amino acids and analogs as chemotherapeutic agents | QUADRIGA BIOSCIENCES, INC. (US) | 2016-07-19 | — | — | US | disclosed |
| WO-2015117146-A1 | BETA-SUBSTITUTED GAMMA-AMINO ACIDS AND ANALOGS AS CHEMOTHERAPEUTIC AGENTS | QUADRIGA BIOSCIENCES, INC. (US) | 2015-08-06 | — | — | WO | disclosed |
| US-20150218085-A1 | BETA-SUBSTITUTED GAMMA-AMINO ACIDS AND ANALOGS AS CHEMOTHERAPEUTIC AGENTS | QUADRIGA BIOSCIENCES, INC. | 2015-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160289168-A1 | BETA-SUBSTITUTED GAMMA-AMINO ACIDS AND ANALOGS AS CHEMOTHERAPEUTIC AGENTS | SLC3A2, SLC7A1, SLC43A1 | MAPT 718/4885ALDH1A1 632/4885HPGD 3661/4885 |
| US-20150218085-A1 | BETA-SUBSTITUTED GAMMA-AMINO ACIDS AND ANALOGS AS CHEMOTHERAPEUTIC AGENTS | SLC3A2, SLC7A1, SLC43A1 | MAPT 718/4885ALDH1A1 632/4885HPGD 3661/4885 |
| US-20170246135-A1 | BETA-SUBSTITUTED GAMMA-AMINO ACIDS AND ANALOGS AS CHEMOTHERAPEUTIC AGENTS | SLC3A2, SLC7A1, SLC43A1 | MAPT 718/4885ALDH1A1 632/4885HPGD 3661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.